港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

医药外包概念

1,779.484

-13.557-0.76%

涨家数：2

跌家数：5

平家数：1

市盈率：- -

高：1,840.451

开：1,793.941

低：1,762.516

收：1,793.042

数据加载中...

快讯：恒指高开0.89% 科指涨1.14%药明生物涨超2%

翰森制药(03692.HK)HS-10561胶囊临床试验获批

阿斯达克财经

翰森制药获批HS-10561胶囊临床试验

翰森制药(03692)：HS-10561胶囊获国家药品监督管理局签发的药物临床试验批准通知书

头对头单药击败K药后，依沃西牵手辉瑞ADC

中证沪深港生物科技主题指数报1180.50点，前十大权重包含药明生物等

【盟科药业：全资子公司盟科美国对Medpace提起诉讼】盟科药业公告称，公司全资子公司盟科美国于2025年2月24日收到美国俄亥俄州南区联邦地区法院西部分院起诉立案确认通知，盟科美国诉Medpace合同纠纷一案已完成起诉立案。盟科美国请求判令Medpace赔偿因违反合同义务和不当行为导致的损失、成本和费用以及利息，具体金额将在庭审中证明。目前案件尚未开庭审理，最终实际影响需以后续法院判决或执行结果为准。公司已完成注射用MRX-4的中国III期临床试验，本次诉讼事宜不涉及对该试验的影响。

通化东宝(600867.SH)：注射用THDBH120获降糖适应症Ib期临床试验总结报告

通化东宝(600867.SH)：GLP-1/GIP双靶点受体激动剂获得降糖适应症Ib期临床试验总结报告

赛诺菲(SNY.US)与梯瓦(TEVA.US)共同开发的duvakitug预计在下半年启动3期临床试验

PCHi 2025观察：珠光颜料成彩妆“风向标”，多肽为个护品类“掌中宝”

港股异动 | 康方生物(09926)涨超5% 依沃西将与辉瑞多个ADCs药物开展联合疗法临床试验

昭衍新药盘中异动临近午盘大幅拉升5.11%报13.980港元

【AH互动】康希诺生物涨近11% A股升逾5% DTcPHib-MCV4联合疫苗获批开展临床试验

方达控股盘中异动股价大涨5.69%报1.300港元

康希诺生物持续上涨逾12% DTcP-Hib-MCV4联合疫苗获得药物临床试验批准

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1576/news?page=11"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"医药外包概念","latestPrice":1779.4844,"timestamp":1741593960102,"preClose":1793.0419,"halted":0,"volume":78441214,"delay":0,"changeRate":-0.007561,"change":-13.557495,"pbRate":2.65369,"amount":1730276101,"amplitude":0.043465,"prevYearClose":1395.7731,"fiveDayClose":1689.63,"twentyDayClose":1618.242,"turnoverRate":0.006914,"marketCap":379404801152,"floatMarketCap":166674436992,"peRate":33.079805},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1840.4508,"amplitude":0.043465,"preClose":1793.0419,"low":1762.5157,"pbRate":"2.65369","latestPrice":1779.4844,"volume":78441214,"delay":0,"open":1793.9412,"prevYearClose":1395.7731,"prevWeekClose":1793.042,"prevMonthClose":1699.456,"prevQuarterClose":1395.773,"fiveDayClose":1689.63,"twentyDayClose":1618.242,"sixtyDayClose":1409.843,"secType":"PLATE","market":"HK","turnoverRate":0.006914,"peRate":33.079805,"marketCap":379404801152,"floatMarketCap":166674436992,"timestamp":1741593960102,"nameCN":"医药外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":2,"down":5,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:16,pageCount:11,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514022564","title":"快讯：恒指高开0.89% 科指涨1.14%药明生物涨超2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514022564","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514022564?lang=zh_cn&edition=fundamental","pubTime":"2025-02-26 09:20","pubTimestamp":1740532800,"startTime":"0","endTime":"0","summary":"　　2月26日消息，美股周二个别发展，市场忧虑关税措施影响经济表现，科技股表现受压，标普500指数及纳指连续第四个交易日下跌，道指则表现向好，三大指数收市升跌不一。美元走势向下，美国十年期债息下滑至4.29厘水平，金价及油价亦出现调整。　　今日港股三大指数集体高开，恒生指数涨0.89%，报23238.34点，恒生科指涨1.14%，国企指数涨0.82%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-02-26/doc-inemukxi3765772.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0516423091.SGD","LU1794554557.SGD","SG9999002463.SGD","LU0327786744.USD","LU0516422366.SGD","LU1242518931.SGD","LU0051755006.USD","HSImain","BK1576","HHImain","BK1521","02833","LU0043850808.USD","SG9999002562.SGD","LU0456827905.SGD","MHImain","LU0140636845.USD","LU0417516738.SGD","HSI","LU0588546209.SGD","LU0572944931.SGD","LU0326950275.SGD","IE00B0JY6N72.USD","LU0979878070.USD","LU0417516902.SGD","LU0320764599.SGD","LU0181495838.USD","LU0516423174.USD","LU0708995583.HKD","BK1610","BK1141","MCHmain","YANG","02269","LU0348735423.USD","LU1880383366.USD","BK1589","LU0348825331.USD","LU0359201612.USD","HSTECH","LU0823426480.USD","LU0823426308.USD","LU0307460666.USD","LU1720050803.USD","LU0516422440.USD","LU1688375341.USD","513600","LU0856984785.SGD","LU0516422952.EUR","LU0819121731.USD"],"gpt_icon":0},{"id":"2514013495","title":"翰森制药(03692.HK)HS-10561胶囊临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2514013495","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514013495?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 23:13","pubTimestamp":1740496380,"startTime":"0","endTime":"0","summary":"翰森制药(03692.HK) 公布，集团与广州麓鹏制药合作的1类小分子布鲁顿酪氨酸激酶抑制剂HS-10561胶囊获中国国家药品监督管理局签发的药物临床试验批准通知书，拟开展用于慢性自发性荨麻疹的临床试验。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-25 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20201021164015908_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20201021164015908_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1420091/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1589","BK1576","BK1141","BK1583","BK1191","03347","03692"],"gpt_icon":0},{"id":"2514062201","title":"翰森制药获批HS-10561胶囊临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2514062201","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514062201?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 18:58","pubTimestamp":1740481132,"startTime":"0","endTime":"0","summary":"2月25日，翰森制药（03692）发布公告，宣布其与广州麓鹏制药有限公司合作的1类小分子布鲁顿酪氨酸激酶抑制剂HS-10561胶囊，已获得中国国家药品监督管理局签发的药物临床试验批准通知书。该临床试验计划用于慢性自发性荨麻疹的治疗，标志着公司在研发领域的重要进展。此次获批的HS-10561胶囊是公司在创新药物开发方面的又一里程碑，显示了公司在生物制药领域的实力与潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502253329160477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1589","03347","03692","BK1576","BK1191","BK1141","BK1583"],"gpt_icon":0},{"id":"2514064671","title":"翰森制药(03692)：HS-10561胶囊获国家药品监督管理局签发的药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2514064671","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514064671?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 18:50","pubTimestamp":1740480644,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)发布公告，于2025年2月24日，集团与广州麓鹏制药有限公司合作的1类小分子布鲁顿酪氨酸激酶抑制剂(BTKi) HS-10561胶囊获中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书，拟开展用于慢性自发性荨麻疹的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03692","03347","BK1141","BK1191","BK1589","BK1576","BK1583"],"gpt_icon":0},{"id":"2514402095","title":"头对头单药击败K药后，依沃西牵手辉瑞ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=2514402095","media":"医药地理","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514402095?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 17:36","pubTimestamp":1740476179,"startTime":"0","endTime":"0","summary":"依沃西+ADC联合治疗实体瘤2025年2月24日，Summit Therapeutics公布2024年财报，披露了研发管线最新进展，同时宣布与辉瑞达成临床合作，开展PD-1/VEGF依沃西+ADC联合治疗实体瘤的临床探索。伊沃西—创新药的“国货之光”伊沃西是全球首个“肿瘤免疫PD-1+抗血管VEGF”机制的双抗新药。击败K药后，依沃西临床试验最新进展Summit表示，仅在2024年，伊沃西就成为了多个医疗会议的焦点，获得了5场口头报告的机会，并发表了14篇论文，覆盖7种肿瘤类型。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225203409abdc61da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225203409abdc61da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03347","BK1161","IE00B5MMRT66.SGD","BK1574","BK1576","09926","IE00B543WZ88.USD","IE00BPRC5H50.USD","BK1141","LU0348783233.USD","LU2488822045.USD","LU1720050803.USD","LU1794554557.SGD","LU0348784397.USD","BK1583","LU0417516571.SGD"],"gpt_icon":0},{"id":"2514682770","title":"中证沪深港生物科技主题指数报1180.50点，前十大权重包含药明生物等","url":"https://stock-news.laohu8.com/highlight/detail?id=2514682770","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514682770?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 17:08","pubTimestamp":1740474516,"startTime":"0","endTime":"0","summary":"数据统计显示，中证沪深港生物科技主题指数近一个月上涨13.10%，近三个月上涨9.40%，年至今上涨12.38%。据了解，中证沪深港生物科技主题指数从内地与香港市场选取50家业务涉及生物药品、制药与生物科技服务等领域的上市公司作为指数样本公司，反映内地与香港市场生物科技主题上市公司证券的整体表现。从中证沪深港生物科技主题指数持仓样本的行业来看，生物药品占比40.60%、化学药占比23.94%、制药与生物科技服务占比23.91%、医疗器械占比11.56%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/25170848371986.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0417516902.SGD","LU1720050803.USD","LU0417516738.SGD","LU0456846285.SGD","LU0572944931.SGD","LU0327786744.USD","LU0051755006.USD","02269","LU0052750758.USD","LU0823426480.USD","IE00B0JY6N72.USD","LU0140636845.USD","LU0348735423.USD","LU0516423174.USD","LU1688375341.USD","SG9999002562.SGD","BK1610","159982","LU1242518931.SGD","SG9999002463.SGD","LU0823426308.USD","LU0708995583.HKD","LU1242518857.USD","BK1576","159837","LU0348825331.USD","LU0359202008.SGD","LU0307460666.USD","LU0516422440.USD","LU0856984785.SGD","LU0039217434.USD","LU1880383366.USD","LU0326950275.SGD","LU0516422366.SGD","LU0359201612.USD","LU0043850808.USD","LU0516422952.EUR","BK1141","LU1794554557.SGD","LU0819121731.USD","LU0181495838.USD","LU0516423091.SGD","LU0588546209.SGD","LU0320764599.SGD","LU2039709279.SGD","BK1589","399300","LU0456827905.SGD","LU0979878070.USD","BK1521"],"gpt_icon":1},{"id":"2514705049","title":"【盟科药业：全资子公司盟科美国对Medpace提起诉讼】盟科药业公告称，公司全资子公司盟科美国于2025年2月24日收到美国俄亥俄州南区联邦地区法院西部分院起诉立案确认通知，盟科美国诉Medpace合同纠纷一案已完成起诉立案。盟科美国请求判令Medpace赔偿因违反合同义务和不当行为导致的损失、成本和费用以及利息，具体金额将在庭审中证明。目前案件尚未开庭审理，最终实际影响需以后续法院判决或执行结果为准。公司已完成注射用MRX-4的中国III期临床试验，本次诉讼事宜不涉及对该试验的影响。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514705049","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514705049?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 16:51","pubTimestamp":1740473510,"startTime":"0","endTime":"0","summary":"盟科药业公告称，公司全资子公司盟科美国于2025年2月24日收到美国俄亥俄州南区联邦地区法院西部分院起诉立案确认通知，盟科美国诉Medpace合同纠纷一案已完成起诉立案。盟科美国请求判令Medpace赔偿因违反合同义务和不当行为导致的损失、成本和费用以及利息，具体金额将在庭审中证明。目前案件尚未开庭审理，最终实际影响需以后续法院判决或执行结果为准。公司已完成注射用MRX-4的中国III期临床试验，本次诉讼事宜不涉及对该试验的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/25165148371308.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03347","BK4127","BK1576","688373","MRX","BK1141","III","BK4134","BK0239","BK1583"],"gpt_icon":0},{"id":"2514541900","title":"通化东宝(600867.SH)：注射用THDBH120获降糖适应症Ib期临床试验总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2514541900","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514541900?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 16:12","pubTimestamp":1740471148,"startTime":"0","endTime":"0","summary":"智通财经APP讯，通化东宝(600867.SH)公告，公司全资子公司东宝紫星(杭州)生物医药有限公司(简称“东宝紫星”)完成了一项关键Ib期临床试验(“在中国成人2型糖尿病患者中评价注射用THDBH120多次给药的安全性、耐受性、药代动力学和药效动力学的随机、双盲、安慰剂对照的Ib期临床研究”)并获得临床试验总结报告，研究结果显示达到主要终点目标。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0188","600867","BK1576","BK1141","BK0239","BK1583","03347"],"gpt_icon":0},{"id":"2514549320","title":"通化东宝(600867.SH)：GLP-1/GIP双靶点受体激动剂获得降糖适应症Ib期临床试验总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2514549320","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514549320?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 16:09","pubTimestamp":1740470979,"startTime":"0","endTime":"0","summary":"格隆汇2月25日丨通化东宝公布，全资子公司东宝紫星（杭州）生物医药有限公司完成了一项关键Ib期临床试验并获得临床试验总结报告，研究结果显示达到主要终点目标。公司在获得注射用THDBH120药物临床试验批准后，根据国内化学药品创新药相关指导原则，近日完成了一项“在中国成人2型糖尿病患者中评价注射用THDBH120多次给药的安全性、耐受性、药代动力学和药效动力学的随机、双盲、安慰剂对照的Ib期临床研究”，研究结果达到了主要终点目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/25160948369004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","03347","600867","BK0188","BK4144","BK1141","GLP","BK0196","BK1576","BK4590","BK1583"],"gpt_icon":0},{"id":"2514803042","title":"赛诺菲(SNY.US)与梯瓦(TEVA.US)共同开发的duvakitug预计在下半年启动3期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2514803042","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514803042?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 14:33","pubTimestamp":1740465193,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，赛诺菲与梯瓦日前公布了其共同开发的在研单抗duvakitug在2b期临床试验RELIEVE UCCD中获得的详细结果。新闻稿表示，这一结果展现了duvakitug成为“best-in-class”疗法的潜力。两家公司预计在今年下半年启动3期临床试验。2b期临床试验数据显示，接受duvakitug治疗的UC患者中，36%的低剂量组和48%高剂量组患者实现临床缓解，此数值在安慰剂组仅为20%。靶向TL1A有望缓解IBD患者的过度免疫反应。赛诺菲与梯瓦在2023年达成合作，共同开发并商业化duvakitug，用于治疗UC和CD。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253916.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK4596","BK1576","BK4584","BK4559","BK1141","BK1583","BK4557","BK4585","BK4588","IE00BFXG1179.USD","BK4007","BK4566","TEVA","SNY"],"gpt_icon":0},{"id":"2514667058","title":"PCHi 2025观察：珠光颜料成彩妆“风向标”，多肽为个护品类“掌中宝”","url":"https://stock-news.laohu8.com/highlight/detail?id=2514667058","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514667058?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 14:16","pubTimestamp":1740464218,"startTime":"0","endTime":"0","summary":"第15届中国国际化妆品个人及家庭护理用品原料展览会于2月19-21日在广州举办。根据展会信息，PCHi 2025汇聚全球20多个国家，800家化妆品原料、检测、设备相关企业参展，展览面积超过6万平方米。PCHi展会历来是业内人士的必争之地，而PCHi 2025更是为参展企业提供了一个展示自身实力、提升品牌形象的绝佳舞台。由于衰老是所有化妆品消费者所面临的共同“难题”，因此对延缓个体或生物体衰老过程，成为护肤行业经久不衰，热度最高的主题。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/OWQ4NGY3MGJmOTZjMTUwZjdhOTdjYjQwNjE1MDM0NDE4NQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/OWQ4NGY3MGJmOTZjMTUwZjdhOTdjYjQwNjE1MDM0NDE4NQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1953846","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2045819591.USD","06616","BK1207","BK1587","LU1046422090.SGD","LU2125910500.SGD","LU2488822045.USD","LU0052750758.USD","02145","02359","06821","01318","BK1576","BK1141","BK1583","LU0708995583.HKD","BK1191","LU2242644610.SGD","02367","LU0320764599.SGD","BK1129"],"gpt_icon":0},{"id":"2514034005","title":"港股异动 | 康方生物(09926)涨超5% 依沃西将与辉瑞多个ADCs药物开展联合疗法临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2514034005","media":"智通财经","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514034005?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 13:41","pubTimestamp":1740462061,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物涨超5%，截至发稿，涨4.81%，报71.95港元，成交额9.44亿港元。消息面上，2月24日，康方生物宣布，依沃西国际市场开发合作伙伴Summit Therapeutics已与辉瑞达成临床试验合作，共同推进康方生物自主研发的PD-1/VEGF双抗依沃西与辉瑞多款抗体偶联药物在多种实体瘤中的联合治疗应用。公司指，此次合作的目标是深入挖掘依沃西联合辉瑞多款vedotin系列ADCs药物联合疗法在多种实体瘤中的协调潜力，加速推进可能重塑治疗格局的创新联合疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE000M9KFDE8.USD","BK1576","IE00B543WZ88.USD","BK4588","IE00BPRC5H50.USD","SG9999011175.SGD","SG9999003800.SGD","LU1066051498.USD","LU0348784397.USD","SG9999001176.SGD","BK4568","BK4581","LU0170899867.USD","LU0456855351.SGD","LU1894683264.USD","LU0306806265.USD","PFE","SG9999002232.USD","BK4592","SG9999001176.USD","LU0289739699.SGD","03347","BK1574","LU0234572021.USD","09926","SGXZ57979304.SGD","LU0122379950.USD","LU1794554557.SGD","BK4007","SG9999013999.USD","LU0321505439.SGD","LU0868494617.USD","LU0225771236.USD","LU0225284248.USD","LU0348783233.USD","SG9999002224.SGD","IE00BLSP4452.SGD","IE00BLSP4239.USD","IE00B19Z3B42.SGD","IE00BBT3K403.USD","LU1023059063.AUD","LU1894683348.USD","LU0058720904.USD","IE00B19Z3581.USD","BK1141","LU2488822045.USD","LU1720050803.USD","BK4585","BK4550","LU0985481810.HKD"],"gpt_icon":0},{"id":"2514035722","title":"昭衍新药盘中异动 临近午盘大幅拉升5.11%报13.980港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514035722","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514035722?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 11:53","pubTimestamp":1740455597,"startTime":"0","endTime":"0","summary":"2025年02月25日临近午盘11时53分，昭衍新药股票出现异动，股价急速拉升5.11%。截至发稿，该股报13.980港元/股，成交量251.577万股，换手率2.11%，振幅10.38%。资金方面，该股资金流入1375.07万港元，流出1499.68万港元。昭衍新药股票所在的生物技术行业中，整体涨幅为1.35%。其相关个股中，创胜集团-B、康希诺生物、基石药业-B涨幅较大，振幅较大的相关个股有药明巨诺-B、康希诺生物、腾盛博药-B，振幅分别为18.40%、17.64%、16.82%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225115317a252c989&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225115317a252c989&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1576","06127"],"gpt_icon":0},{"id":"2514038757","title":"【AH互动】康希诺生物涨近11% A股升逾5% DTcPHib-MCV4联合疫苗获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2514038757","media":"金吾资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514038757?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 11:15","pubTimestamp":1740453354,"startTime":"0","endTime":"0","summary":"金吾财讯 | 康希诺生物 早盘股价强势走高，暂报38港元，涨幅10.79%，成交额1.24亿港元。消息面上，公司近日公告称，公司研发的吸附无细胞百(组分)白破b型流感嗜血杆菌(结合)-ACYW135群脑膜炎球菌(结合)联合疫苗已获得中国国家药品监督管理局批准，可以开展相关临床试验。对此，公司回应称，结合肺炎疫苗市场情况，公司已布局更高价的肺炎结合疫苗，以增强肺炎产品组合的竞争力，尚处于临床前的开发阶段，未来如有阶段性进展，将及时分享。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225111617962f498e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225111617962f498e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1576","BK1141","06185","BK1574","BK1191","BK1583","BK1515","03347"],"gpt_icon":0},{"id":"2514038784","title":"方达控股盘中异动 股价大涨5.69%报1.300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514038784","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514038784?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 11:11","pubTimestamp":1740453066,"startTime":"0","endTime":"0","summary":"2025年02月25日早盘11时11分，方达控股股票出现异动，股价急速拉升5.69%。截至发稿，该股报1.300港元/股，成交量201万股，换手率0.10%，振幅8.13%。资金方面，该股资金流入190.026万港元，流出43.802万港元。机构评级方面，在所有1家参与评级的机构中，100%的券商给予卖出建议，无券商给予买入、持有建议。方达控股股票所在的生物技术行业中，整体涨幅为0.75%。该公司的部门包括北美和欧洲以及中国。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225111106abdbb89f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225111106abdbb89f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01521","BK1576","BK1141","BK1583"],"gpt_icon":0},{"id":"2514038954","title":"康希诺生物持续上涨逾12% DTcP-Hib-MCV4联合疫苗获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2514038954","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514038954?lang=zh_cn&edition=fundamental","pubTime":"2025-02-25 11:05","pubTimestamp":1740452700,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　康希诺生物（06185）早盘持续走高，股价上涨12.54%，现报38.60港元，成交额1.14亿港元。\n　　康希诺生物公布，公司研发的吸附无细胞百（组分）白破（“DTcP”）b型流感嗜血杆菌（结合）（“Hib”）-ACYW135群脑膜炎球菌（结合）（“MCV4”）联合疫苗（“DTcPHib-MCV4联合疫苗”）已获得中国国家药品监督管理局批准，可以开展相关临床试验。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-02-25/doc-inemsfym1428950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","03347","BK1515","BK1161","BK1141","BK1574","BK1191","BK1576","06185"],"gpt_icon":0}],"pageSize":16,"totalPage":13,"pageCount":11,"totalSize":201}]}}